PhorMed, Inc., a clinical stage biopharmaceutical company founded in 2019, is developing a drug internally called RP-323 or 12-O-tetradecanoylphorbol-13-acetate (TPA) aka phorbol-12-myristate-13-acetate (PMA).<br><br>
PhorMed focuses on the development of human therapeutics that function at the cellular level, a cell repair therapy that targets along multiple cell lines, and fortunately these targets are important for the pathogenesis of several diseases, allowing it to become a Platform Technology. Our area of study covers Oncology/Hematology, Neurology and Anti-Inflammatory.
The company’s goal is to become first-line treatments for the disease states we are studying and potentially be a new drug class for Anti-Inflammation and Neurology.
Molecule
Active Platforms
A Myriad of Lateral Platforms
What is RP-323?
RP-323 is PhorMed’s groundbreaking therapeutic compound, developed to address life-threatening diseases in oncology, neurology, and inflammatory conditions. It represents a new class of precision medicine, designed to treat complex diseases with high efficacy while minimizing side effects.
RP-323 is a molecule derived from the oil of the Croton tiglium L. plant, a leafy shrub native to Southeast Asia. RP-323 is now synthesized.
RP-323 Molecule
Croton Tiglium L.
Five indications are presently in the pipeline and the company will continue to expand through it’s continued dedication in research and development We are committed to the highest standards of scientific excellence and integrity to accomplish these goals for our patients and society.
A Versatile, Targeted Approach
RP-323 is engineered to target the underlying mechanisms of disease, making it effective across a wide range of conditions:
- Oncology: Treating Acute Myeloid Leukemia (AML) and Hodgkin’s Lymphoma by targeting and disrupting the growth pathways of cancer cells.
- Neurology: Crossing the blood-brain barrier to address neurodegenerative diseases like Parkinson’s, protecting and repairing brain cells.
- Inflammation: Modulating the body’s inflammatory response in Acute Respiratory Distress Syndrome (ARDS), reducing damage caused by cytokine storms.
By addressing unmet medical needs in oncology, neurology, and inflammatory diseases, RP-323 has the potential to transform lives.